Reviewer's report

Title: A Chinese patient with 11β-hydroxylase deficiency due to novel compound heterozygous mutation in CYP11B1 gene: a case report

Version: 1 Date: 21 May 2018

Reviewer: CLAUDIO Kater

Reviewer's report:

The authors state at the beginning that 11β-hydroxylase deficiency (11OHD) is the second most common form of congenital adrenal hyperplasia (CAH).

This is only partially true, as it depends on the geographical area and the specific population one is referring to.

Although 11OHD is generally regarded as the second most common form of CAH in Jews of Moroccan origin, Turkish descents, and Chinese of Han origin, it is surpassed by 17α-hydroxylase deficiency (17OHD) in Canadian Mennonites, individuals residing in the Friesland region of the Netherlands, in Brazil, and also in part of China [Han B, Xue L, Fan M, et al. Endocrine. 2016;53:784].

Although the authors correctly mentioned the prolonged use of excess glucocorticoid to treat their patient (0.75mg/d of dexamethasone) which resulted in marked Cushingoid features, it is also appropriate to point that substitution for Prednisone 7.5mg/d is unsafe as well, because it is still in the pharmacologic range.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.